9，9’-（1，4-亚苯基）十四氢-二-吖啶-1，1＇,8，8’-四酮缩双季戊四醇的合成

利用1，3-环己二酮和1，4-苯二甲醛为原料，在微酸介质中通过羟醛缩合和脱水反应，合成了9，9’-（1，4-亚苯基）-2H，2’H，3H，3’H，4H，4’H，5H，5H’，6H，6’H，7H，7’H，9H，9’H-十四氢-二-吖啶-1，1’，8，8＇-四酮（化合物Ⅰ）。提出了化合物Ⅰ生成的反应机理。将化合物Ⅰ与季戊四醇在Ⅰ，催化下反应，生成了目标化合物9，9’-（1，4-亚苯基）-2H，2’H，3H，3’H，4H，4’H，5H，5H’，6H，6’H，7H，7’H，9H，9’H-十四氢-二-吖啶-1，1’，8，8’-四酮缩双季戊四醇（化合物Ⅱ），收率为40％。产物和中间体用IR、^1H NMR、MS和元素分析进行了结构表征。在含有螺环单元的化合物Ⅱ^1H NMR中，亚甲基中的8个氢由于受手性轴和苯环的影响而裂分成8重峰。对影响反应的因素特别是副产物生成的原因进行了探讨     

9,9-(′1,4-亚苯基)十四氢-二-吖啶-1,1,′8,8′-四酮缩双季戊四醇的合成

利用1,3-环己二酮和1,4-苯二甲醛为原料,在微酸介质中通过羟醛缩合和脱水反应,合成了9,9′-(1,4-亚苯基)-2H,2′H,3H,3′H,4H,4′H,5H,5H,′6H,6′H,7H,7′H,9H,9′H-十四氢-二-吖啶-1,1,′8,8′-四酮(化合物Ⅰ)。提出了化合物Ⅰ生成的反应机理。将化合物Ⅰ与季戊四醇在I2催化下反应,生成了目标化合物9,9-(′1,4-亚苯基)-2H,2′H,3H,3′H,4H,4′H,5H,5H,′6H,6′H,7H,7′H,9H,9′H-十四氢-二-吖啶-1,1,′8,8′-四酮缩双季戊四醇(化合物Ⅱ),收率为40%。产物和中间体用IR1、H NMR、MS和元素分析进行了结构表征。在含有螺环单元的化合物Ⅱ1H NMR中,亚甲基中的8个氢由于受手性轴和苯环的影响而裂分成8重峰。对影响反应的因素特别是副产物生成的原因进行了探讨     

螺环三代树形大分子化合物的合成

以对苯二甲醛单缩醛与季戊四醇反应得到了2,4,8,10-四氧杂-2,9-二(4-二氰基乙烯基苯基)螺[5.5]十一烷(1), 经水解, 再与丙二腈反应, 制备了中间体2,4,8,10-四氧杂-2-(4-二氰基乙烯基苯基)-9-(4-甲酰基苯基)螺[5.5]十一烷(3). 8-(4-氧代环己烷基)-1,4-二氧杂螺[4.5]癸烷经芳构化形成2,6,10-三-(4-氧代环己烷基)-1,2,3,4,5,6,7,8,9,10,11,12-十二氢苯并[l]菲(4), 再与甲醛进行羟醛缩合, 制成了2,6,10-三-(4-羟基-3,3,5,5-四羟甲基环己烷基)-1,2,3,4,5,6,7,8,9,10,11,12-十二氢苯并[l]菲(5), 将5与过量的3反应, 得到了目标树形大分子化合物2,6,10-三-{15-(3,11-二(-4-(3-((9-(4-二氰基乙烯基)苯基)2,4,8,10-四氧杂螺[5.5]十一烷基)))-7-羟基-二螺[5.1.5.3]十六烷基)}-1,2,3,4,5,6,7,8,9,10,11,12-十二氢苯并[l]菲(6), 收率为18.1%. 产品结构经IR, 1H NMR, MS和元素分析进行了表征. 对影响反应的因素进行讨论.     

9,9''''-(1,4-亚苯基)十四氢-二-吖啶-1,1'''',8,8''''-四酮缩双季戊四醇的合成

利用1,3-环己二酮和1,4-苯二甲醛为原料,在微酸介质中通过羟醛缩合和脱水反应,合成了9,9'-(1,4-亚苯基)-2H,2'H,3H,3'H,4H,4'H,5H,5H',6H, 6'H,7H,7'H,9H,9'H-十四氢-二-吖啶-1,1',8,8'-四酮(化合物Ⅰ). 提出了化合物Ⅰ生成的反应机理. 将化合物Ⅰ与季戊四醇在I2催化下反应,生成了目标化合物9,9'-(1,4-亚苯基)-2H,2'H,3H,3'H,4H, 4'H,5H,5H',6H,6'H,7H,7'H,9H,9'H-十四氢-二-吖啶-1,1',8,8'-四酮缩双季戊四醇(化合物Ⅱ),收率为40%. 产物和中间体用IR、1H NMR、MS和元素分析进行了结构表征. 在含有螺环单元的化合物Ⅱ1H NMR中,亚甲基中的8个氢由于受手性轴和苯环的影响而裂分成8重峰.对影响反应的因素特别是副产物生成的原因进行了探讨     

3-烷基/芳基-6-(2', 4'-二氯苯基)-7H-1, 2, 4-三唑[3, 4-b]- 1, 3, 4-噻二 嗪的合成及波谱性质

以间二氯苯与氯乙酰氯反应,生成ω-氯代-2,4-二氯苯乙酮(1),再使之分别与3-烷基/芳基-4-氨基-5-巯基-1,2,4-三唑(2a～2l)反应,合成了12种新的3-烷基/芳基-6-(2',4'-二氯苯基)-7H-1,2,4-三唑并[3,4-b]1,3,4-噻二嗪(4a～4l)。利用EA,IR,^1HNMR确定了其结构,并提出该反应的可能机制。     

含氮杂环多芳基咪唑衍生物的合成及其光物理性能

以冰醋酸为溶剂和催化剂,苯偶酰/9,10-菲醌、3-吲哚甲醛/3-咔唑甲醛及醋酸铵经"一锅"反应高效合成了系列含吲哚或咔唑结构单元的多取代咪唑衍生物.考察了反应物配比、溶剂的选择和用量及温度等因素对反应的影响,研究了所合成化合物的光物理性能;筛选出对p H值敏感且结构独特的两个化合物作为p H荧光探针,检测在其作用下MCF-7细胞在不同p H值环境中的荧光成像,结果表明探针2-(9-苄基-9H-咔唑-3-基)-4,5-二苯基-1H-咪唑(2d)和2-(9-苄基-9H-咔唑-3-基)-1H-菲并[9,10-d]咪唑(4)都可用作检测活细胞内p H变化的p H荧光探针.     

新型地氯雷他定酰胺衍生物的合成及其利尿活性

以地氯雷他定和对硝基苯甲酰氯为原料,三乙胺为缚酸剂,经N-酰化反应制得{4-[8-氯-5H-苯并[5,6]环庚并[1,2-b]吡啶-11(6H)-亚基]哌啶-1-基}(4-硝基苯基)甲酮(3);3在酸性条件下经SnCl2还原得中间体(4)。以吡啶为缚酸剂和溶剂,4与烷基酰氯(或苯酰氯)经酰化反应合成了7个具有潜在AVP-V2受体拮抗活性的新型地氯雷他定酰胺衍生物(6a~6g),其结构经1H NMR和HR-MS表征。SD大鼠利尿活性实验表明,6a~6g均有一定的利尿活性,其中N-【4-{4-[8-氯-5H-苯并[5,6]环庚烷并[1,2-b]吡啶-11(6H)-亚基]哌啶-1-羰基}苯基】丙酰胺的利尿活性与托伐普坦相当。     

腈亚胺的1,3-偶极环加成反应合成螺吡唑-吡咯里嗪类化合物

通过2-芳亚甲基-2,3-二氢-1H-吡里-1-酮与腈亚胺[经苯甲酰氯苯腙(2)与三乙胺反应生成]的1,3-偶极环加成反应,以较高收率合成了一系列的4-芳基-2,5-二苯基-2H,4H-二氢-螺[吡唑-3,2’-吡咯里嗪]-1’(3’H)-酮.采用NMR,IR,质谱和元素分析等多种谱学技术对产物进行了结构表征.     

2-芳基吲哚的敏化光氧化偶合反应

本文研究了十七种2-芳基吲哚(1a-1q)在甲醇-乙酸介质中的亚甲基蓝(MB)敏化光氧化反应, 发现有十五种吲哚(1a-1o)以85%-95%的产率给出2,2'-二芳基-[2,3'-联-1H-吲哚]-3(2H)-酮(2a-2o), 而2-(4-硝基苯基]吲哚(1p)和2-联苯基吲哚(1q)则分别生成2-甲氧基-2-(4-硝基苯基)-1,2-二氢-3H-吲哚-3-酮(7p)和2-联苯基-4H-3,1-苯并恶嗪-4-酮(11q), 其中7p在分离过程中失去甲醇分子给出2-(4-硝基苯基)-3H-吲哚-3-酮(10p)。     

水介质中9,10-二芳基吖啶的洁净合成

水介质中在十二烷基磺酸钠(SDS)催化下, 席夫碱与双甲酮反应合成了一系列9,10-二芳基吖啶衍生物, 同时分离得到一种中间产物. 所有产物的结构通过红外光谱和1H NMR光谱确定, 产物10-(4-氯苯基)-9-(4-甲氧基苯基)-3,3,6,6-四甲基-3,4,6,7,9,10-六氢化吖啶-1,8(2H,5H)-二酮(3i)和中间产物2-{4-氯苯基-[2-(4-甲氧基苯基氨基)-4,4-二甲基-6-氧代环已-1-烯基]甲基}-3-羟基-5,5-二甲基环已-2-烯酮(4h)的结构还通过单晶X射线衍射分析确证.     

α,β,γ,δ-四-{4-[3-(9-(4-(3-(9-(4-(2-(5,5-二酰氧基甲基-1,3-二噁烷基))))苯基-2,4,8,10-四氧杂螺[5.5]十一烷基)))苯基-2,4,8,10-四氧杂螺[5.5] 十一烷基]}苯基卟啉星形化合物的合成

以对苯二甲醛、丙二腈、季戊四醇和吡咯为原料, 合成了含有螺环结构单元的中间体3-[4-(2,2-二氰基)乙烯基]苯基-9-(4-甲酰基)苯基-2,4,8,10-四氧杂螺[5.5]十一烷(3)和α,β,γ,δ-四-(4-甲酰基苯基)卟啉(4). 4与过量的季戊四醇反应, 得到α,β,γ,δ-四-{4-[2-(5,5-二羟甲基-1,3-二噁烷基)]}苯基卟啉(5), 5与3的反应产物经10% NaOH 处理后, 再与过量的季戊四醇反应, 得到α,β,γ,δ-四-{4-[3-(9-(4-(3-(9-(4-(2-(5,5-二羟甲基-1,3-二噁烷基))))苯基-2,4,8,10-四氧杂螺[5.5]十一烷基)))苯基-2,4,8,10-四氧杂螺[5.5]十一烷基]}苯基卟啉(6), 6与乙酐、丙酐、苯甲酰氯反应, 得到α,β,γ,δ-四-{4-[3-(9-(4-(3- (9-(4-(2-(5,5-二乙酰氧基甲基-1,3-二噁烷基))))苯基-2,4,8,10-四氧杂螺[5.5]十一烷基)))苯基-2,4,8,10-四氧杂螺[5.5]十一烷基]}苯基卟啉(7), α,β,γ,δ-四-{4-[3-(9-(4-(3-(9-(4-(2-(5,5-二丙酰氧基甲基-1,3-二噁烷基))))苯基-2,4,8,10-四氧杂螺[5.5]十一烷基)))苯基-2,4,8,10-四氧杂螺[5.5]十一烷基]}苯基卟啉(8)和α,β,γ,δ-四-{4-[3-(9-(4-(3-(9-(4-(2-(5,5-二苯甲酰氧基甲基-1,3-二噁烷基))))苯基-2,4,8,10-四氧杂螺[5.5]十一烷基)))苯基-2,4,8,10-四氧杂螺[5.5]十一烷基]}苯基卟啉(9)等三种卟啉星形化合物. 中间体1～6和星形化合物7～9均进行了IR, ¹H NMR, MS和元素分析等结构表征. 对影响反应的诸因素进行了讨论.      

无溶剂法合成4,6,10,12,16,18,22,24-八羟基-2,8,14,20-四-{(联三-(3-苯基-2,4,8,10-四氧杂螺[5.5]十一烷基))-(4-(2-(4,6,10,12,16,18,22,24-八羟基)杯芳基)苯基)}杯芳烃螺环树形大分子化合物

以对苯二甲醛、丙二腈为原料, 合成对苯二甲醛单缩醛, 再与季戊四醇反应得到了2,4,8,10-四氧杂-2,9-二(4-二氰基乙烯基苯基)螺[5.5]十一烷, 经水解, 与丙二腈反应, 制备了中间体2,4,8,10-四氧杂-2-(4-二氰基乙烯基苯基)-9-(4-甲酰基苯基)螺[5.5]十一烷(3). 用乙酸酐保护的对苯二甲醛单缩醛与间苯二酚反应, 制备了杯芳烯中间体(6). 将化合物6与过量的化合物3反应, 得到中间体7, 经水解后与过量的化合物6反应, 得到了4,6,10,12,16,18,22,24-八羟基-2,8,14,20-四-{(联三-(3-苯基-2,4,8,10-四氧杂螺[5.5]十一烷基))-(4-(2-(4,6,10,12,16,18,22,24-八羟基)杯芳基)苯基)}杯芳烃螺环树形大分子化合物(9). 总收率为12.7%. 产物结构用IR, 1H NMR, 13C NMR, MS 和元素分析进行了表征, 对影响反应的因素进行了讨论.     

无溶剂法合成杯[4]芳烯星形化合物

以对苯二甲醛、乙酸酐为原料合成对苯二甲醛单缩醛, 接着与间苯二酚反应, 制备了含醛基杯[4]芳烯. 利用季戊四醇与含醛基杯[4]芳烯反应, 进而再与3-[4-(2,5-二氧杂环戊基)苯基]-9-[4-二(甲羰氧基)甲基苯基]-2,4,8,10-四氧杂螺环[5.5]十一烷反应, 合成了杯[4]芳烯星形化合物, 收率为65.2%. 产品结构经 IR, ¹H NMR, MS 和元素分析进行了表征.     

聚缩醛螺胞二醚的合成及结构表征

在I₂催化剂的作用下, 利用苯甲醛与季戊四醇反应, 制备了聚缩醛螺胞二醚的模型化合物3,9-二苯基-2,4,8,10-四氧杂螺[5.5]十一烷(1). 在此基础上, 利用1,3-苯二甲醛与不同摩尔比的季戊四醇合成了化合物1,3-二(2,6-二氧杂-4,4-二羟甲基环己基)苯(2)和2,4,8,10-四氧杂-3,9-二(3'-甲酰基苯基)螺[5.5]十一烷(3). 化合物2与化合物3反应, 制成标题化合物聚缩醛螺胞二醚4, 收率为95.4%. 用FTIR, ¹H NMR对化合物1～4的结构进行了表征. 发现在含有手性轴化合物1, 3, 4的¹H NMR谱中, 4个亚甲基中的8个氢原子裂分为4组双峰, 而不含有手性轴化合物中的4个亚甲基中的8个氢原子不裂分, 是个单峰. 这种不同不是由于化合物中刚性环所致, 而是由于有无手性轴造成的.     

Synthesis of New Pyrido[4″,3″:4″,5″]thieno[2″,3″:4,5]pyrimido[2,1-b][1,3,4]thiadiazine Derivatives

Ethyl 2-methyl-11-oxo-9, 10-dihydro-1 H , 11 H -pyrido[4",3":4',5']thieno[2',3':4,5]pyrimido[2,1-b][1,3,4]thiadiazine-8(7 H )-carboxylate 7 has been synthesised by the reaction of ethyl 3-amino-4-oxo-2-thioxo-1,3,4,5,6,8-hexahydropyrido[4',3':4,5]thieno[2,3-d]pyrimidine-7(2 H )-carboxylate 2 with allylbromide followed by treatment with bromine and subsequent dehydrobromination of the brominated product 5 with ethanolic sodium hydroxide. Its isomeric ethyl 2-methyl-11-oxo-9,10-dihydro-3 H ,11 H -pyrido[4",3Prime;:4',5']thieno[2',3':4,5]pyrimido[2,1-b][1,3,4]thiadiazine-8(7 H )-carboxylate 8 has been obtained by condensation of 2 with chloroacetone followed by cyclization of the intermediate 9 with p -toulenesulfonic acid. The thiadiazino derivatives 11 , 13 , 15 were prepared through the reaction of 2 with the appropriate f -halocarbonyl compounds followed by cyclization reactions of the intermediates 10 , 12 , 14 .     

新型树状化合物1,3,5-三{3-[2,4,8,10-四氧杂\|9(3,5-二(2,6-二氧杂-4,4-二羟甲基环己基)苯基]螺[5.5]十一烷基}苯的制备

本实验采用季戊四醇与苯三甲醛缩合, 制成树状化合物1,3,5-三{3-|[2,4,8,10-四氧杂-9(3,5-二(2,6-二氧杂-4,4-二羟甲基环己基)苯基)螺[5.5]十一烷基}苯. 该类树状分子具有手性螺环结构, 手性密度很高, 可开发成理想的高效手性催化剂[3~8], 具有诱人的应用前景.     

Synthesis of a 6-aryloxymethyl-5-hydroxy-2,3,4,5-tetrahydro-[1H]-2-benzazepin-4-one: a muscarinic (M3) antagonist

A synthesis of the racemic 6-aryloxymethyl-5-hydroxy-2,3,4,5-[1H]-2-tetrahydrobenzazepin-4-one , for evaluation as a muscarinic (M(3)) antagonist, is described. 2-[2-tert-Butyldimethylsilyloxymethyl-6-(2,6-dimethoxyphenoxymethyl)phenyl]propan-2-ol was prepared from 2,6-dimethyl-1-bromobenzene and taken through to N-[3-(2,6-dimethoxyphenoxymethyl)-2-(propen-2-yl)phenyl]methyl-N-prop-2-enyl 2-nitrobenzene sulfonamide . However, attempts to cyclise this diene by alkene metathesis were unsuccessful, the open-chain alkene being the only product isolated in yields of up to 70%. In a second approach to the 6-aryloxymethyl-5-hydroxytetrahydrobenzazepin-4-one, methyl (Z)-3-[2-(1-tert-butyldimethylsilyloxymethyl)-6-(1,6-dimethoxyphenoxymethyl)phenyl]but-2-enoate was converted into (Z)-3-[2-hydroxymethyl-6-(2,6-dimethoxyphenoxymethyl)phenyl]but-2-enyl 2-nitrobenzene sulfonamide which was cyclised under Mitsunobu conditions to the corresponding 2,3-dihydro-[1H]-2-benzazepine . The structure of this was confirmed by an X-ray crystal structure of its 2-(4-bromophenylsulfonyl) analogue , and functional group modification including hydroxylation, attachment of the requisite side-chain at C(2) and further oxidation gave the target compound which was assayed for muscarinic (M(3)) activity.     

Chiral Separation of Spiro-compounds and Determination Configuration

Chiral spirocyclic compounds have attracted the attention of scholars and scientists owing to their potential applications in the pharmaceutical industry as either active pharmaceutical ingredients, catalysts in synthesizing active enantiomers, or as surface modifiers on silica particles to resolve entantiomers. In this study, five spiro compounds of 3,9-diphenyl-2,4,8,10-tetraoxaspiro[5.5]-undecane（1）, 3,9-（4-methoxyphenyl）-2,4,8,10-tetraoxaspiro [5.5] -undecane（2）, 3,9-（4-methylphenyl）-2,4,8,10-tetraoxaspiro [5.5] -undecane（3）, 4,4＇-（2,4,8,10-tetraoxaspiro[5.5]undecane-3,9-diyl）dibenzoic acid（4） and 3,9-di（4-formyl-phenyl）-2,4,8,10-tetraoxa-spiro[5.5]-undecane（5） were synthesized by grinding pentaerythritol with benzaldehyde, 4-methoxybenzaldehyde, 4-methylbenzaldehyde, 4-carboxybenzaldehyde or terephthalaldehyde monoacetal in the presence of InI3r3 under solvent-free conditions. A normal phase HPLC method was successfully developed to resolve entantiomers of compounds 1--5 on a chiral column. Specific optical rotation of R or S entantiomers（1） was determined and the corresponding configurations were proposed based on Lowe＇s rule.     

A new, easily recyclable arylating agent based on a diphosphino-digold(I) complex

The synthesis of two organogold(I) complexes, [(Au(NCN))2(dppbp)] (6) and [(Au(Phebox))2(dppbp)] (9), and their application in subsequent transmetalating reactions are described. A trinuclear organogold(I) complex, [(AuCl)3(tdpppb)] (4) is also reported, which exhibits a surprisingly high solubility in dichloromethane. It was found that 6 and 9 can cleanly transfer the anionic NCN-([C(6)H(3)(CH(2)NMe(2))2-2,6]-) or Phebox-([2,6-bis(oxazolinyl)phenyl]-) moiety to Ti(IV) and Pd(II) centers, respectively. The coproduct [(AuCl)2(dppbp)] (3, dppbp is [4-Ph(2)PC(6)H(4)]2 (1)) formed during this transmetalation reaction, precipitates almost quantitatively from the reaction mixture (toluene) and can thus be separated by simple filtration. In comparison, [AuCl(PPh3)], formed as the coproduct in the transmetalation reaction of [Au(NCN)(PPh3)] with metal salts, has a higher solubility in apolar solvents and thus is more difficult to separate from the resultant organometallic complex. Digold complex 6 has been characterized by NMR spectroscopy and crystallographic analyses. These analyses show that the two gold units are essentially independent. The formation of a dimetallic transmetalating agent based on gold(I) had no effect on its transmetalating properties.